Colorectal Cancer: Studies with drugs approved by Anvisa have shown unprecedented results in eliminating tumors in 100% of cases. “During the median of 12 months, no patients received chemoradiation therapy or surgical resection.”
The drug, already approved by Amvisa, has surprised the scientific community by eliminating colorectal cancer in 100% of patients being treated. Tests that validated the amazing study came from a small group of 12 patients with rectal cancer. Among them, researchers topically applied a monoclonal antibody called dostarlimab. This led to promising results that lasted for over a year.
The study was published in the New England Journal of Medicine on Sunday 5 and was discussed by oncologists during the American Society of Clinical Oncology (ASCO) annual event, which ended Tuesday. After treatment, test imaging such as magnetic resonance, endoscopy, digital rectal examination or biopsy showed no evidence of tumor presence.
The patient took the drug intravenously every 3 weeks for 6 months. “No patients underwent chemoradiation therapy or surgical resection during the median follow-up of 12 months,” reads an excerpt from the study.
In an interview with The New York Times, oncologist Luis Diaz Jr., one of the authors of the film, said that the success rate of US studies is uncommon and is probably the first time such a thing has been recorded. The whole country mentioned. History of cancer research.
Andrea Selsek, an oncologist and lead author of the study at the Memorial Sloan Kettering Cancer Center in New York, said: “All patients have eliminated their tumors, and no one has ever seen this. I don’t think so. ”
Dostarlimab has been approved for the treatment of endometrial cancer in Brazil and has not previously been tested against other types of tumors. Although promising, this study requires some attention, including the need for long-term follow-up to see if the tumor does not reappear or if metastases appear elsewhere in the body. There is a point.
It is also noted that all volunteers had certain abnormalities in rectal cancer, commonly known as “mismatch repair deficiencies,” which prevent normalization of body function and cause cell mutations. Deserves. This type of abnormality occurs in 5-10% of all patients with rectal cancer.
Patients with rectal cancer have a high survival rate, but conventional treatments can have lifelong sequelae. Examples of sequelae include bowel and bladder dysfunction, sexual dysfunction, and even infertility in young women. Some patients may still have to wear an artificial anal bag permanently.
→ If created here … Consider continuing the work that Pragmatism has been doing for 13 years and helping it reach millions of people. Our journalism has always plagued many, but after Jair Bolsonaro came to power, attempts to silence it became even greater. So it didn’t make much sense to ask for your support. Contribution is important and helps maintain team, structure and freedom of expression. Click here to support us!